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Abstract 
Glioblastoma (GB) is the most frequent and aggressive type of primary brain tumor. Recurrences are mostly 
located at the margin of the resection cavity in the peritumoral brain zone (PBZ). Although it is widely believed 
that infiltrative tumor cells in this zone are responsible for GB recurrence, few studies have examined this zone. 
In this study, we analyzed PBZ left after surgery with a variety of techniques including radiology, 
histopathology, flow cytometry, genomic, transcriptomic, proteomic, and primary cell cultures. The resulting 
PBZ profiles were compared with those of the GB tumor zone and normal brain samples to identify 
characteristics specific to the PBZ. We found that tumor cell infiltration detected by standard histological 
analysis was present in almost one third of PBZ taken from an area that was considered normal both on standard 
MRI and by the neurosurgeon under an operating microscope. The panel of techniques used in this study show 
that the PBZ, similar to the tumor zone itself, is characterized by substantial inter-patient heterogeneity, which 
makes it difficult to identify representative markers. Nevertheless, we identified specific alterations in the PBZ 
such as the presence of selected tumor clones and stromal cells with tumorigenic and angiogenic properties.  
The study of GB-PBZ is a growing field of interest and this region needs to be characterized further. This 
will facilitate the development of new, targeted therapies for patients with GB and the development of 
approaches to refine the per-operative evaluation of the PBZ to optimize the surgical resection of the tumor. 
 
Keywords: Glioblastoma, peritumoral brain zone, genomics, transcriptomics, proteomics, histopathology
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Introduction 
 Glioblastoma (GB) is the most frequent and aggressive type of primary tumor in the central nervous 
system (CNS)[1]. The standard treatment is surgical resection followed by fractionated radiotherapy, with 
concomitant and adjuvant chemotherapy with temozolomide[2]. Despite this treatment, the prognosis remains 
poor with a mean progression-free survival of seven months and an average overall survival of 15 months[1].  
 Gross total resection of GB, which is the first step of therapeutic management, has a major effect on 
overall survival, progression-free survival, and the quality of life of the patient [3, 4]. It is only achieved in 35 to 
50% of cases [5, 6] because the presence of functional areas makes it impossible to perform a resection with safe 
margins and no risk of neurological impairment [4]. Despite complete surgical resection, recurrence happens in 
almost all cases, mostly at the margin of the resection cavity in the peritumoral brain zone (PBZ) [7, 8]. It is 
widely believed that tumor cell infiltration into the PBZ may promote recurrence [9–11]. However, few cellular 
and molecular analyses have been performed in this area. Some studies have shown that residual, unresected 
tumor cells display alterations different from those of cells isolated from the corresponding tumor mass [12–14]. 
A better understanding of the characteristics of the PBZ and tumor cell infiltration in this region is critical to 
unravel the mechanisms underlying the recurrence of GB and to optimize the quality of surgical resection and 
the development of new therapies. 
As part of the “Grand Ouest Glioma Project”, funded by the French National Institute of Cancer, whose 
objective was to study tumor heterogeneity in GB [15–22], we performed a multidisciplinary analysis of the PBZ 
with a variety of techniques including radiology, histopathology, flow cytometry, omic analyses and primary cell 
cultures. The resulting PBZ profiles were compared with those of GB tumor zone (TZ) and normal brain samples 
to identify characteristics specific to the PBZ. 
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Material and methods 
Patient recruitment and brain biopsies 
 Thirty-nine patients with de novo GB were included in the “Grand Ouest Glioma Project”. All patients 
gave informed consent prior to their enrolment. The study protocol was approved by the local ethics committee 
(CPP Ouest II, Angers, France).  
 Image-guided neuronavigation (Brainlab®, La Défense, France) was used during pre-surgical planning 
to define four regions of interest (ROI) in the tumor and its surroundings: the PBZ, the interface zone (IZ), the 
florid tumor zone (TZ), and the central necrotic zone (NZ) (Figure 1A). Biopsies were performed in the selected 
regions and were studied by various techniques: radiology, histopathology, flow cytometry, omic, and cell 
culture analyses and the results of these various methods were compared. All types of analysis could not be 
performed for each PBZ sample due to limited sample size. Among the 39 patients initially included, biopsies 
from 28 patients were analyzed by at least three techniques. 
Radiological analysis 
 Standardized sequences were used for pre-surgical MRI and were carried out in the following order: 
T1-weighted axial and coronal acquisitions, diffusion, a quantitative dynamic contrast-enhanced (DCE) session 
after the injection of gadolinium at a concentration of 0.1 mmol/kg, and finally T2 FLAIR, T2-weighted and 3D 
T1 acquisitions. For a detailed description of the calculation of DCE-MRI variables in all four zones (NZ, TZ, IZ 
and PBZ), see Supplementary Methods.  
Histolopathogical analysis 
 For histopathological analysis, formalin-fixed paraffin-embedded sections of the biopsy specimens were 
stained with hematoxylin–phloxin–saffron (HPS). The diagnosis of GB was made according to the 2007 WHO 
classification of CNS tumors [23]. 
Flow cytometry analysis 
 DNA of cells of the PBZ and those of the TZ from 25 patients was stained by Vindeløv’s protocol [24] 
and the samples were analyzed by flow cytometry (BD Biosciences, Le Pont de Claix, France). DNA index (DI) 
and the percentage of cell populations identified on the basis of different DNA contents were calculated with 
Modfit version 5.2 software (Verity Software House, Topsham, Maine) as previously described [15]. 
Omic analyses 
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 PBZ and TZ samples were used for genomic (n = 10), transcriptomic (n = 9) and proteomic (n = 6) 
analyses. Brain samples from patients who underwent epilepsy surgery were also used as control brain samples. 
For a detailed description of omic analyses, see Supplementary Methods.  
 
Fig. 1: 
A) Example of pre-surgical planning of biopsies on an axial contrast-enhanced T1 MRI brain slide. Blue area: 
necrotic zone (NZ), red area: florid tumor zone (TZ), yellow area: intermediate zone (IZ) and green area: 
peritumoral brain zone (PBZ) 
B) Individual results for quantitative DCE MRI analysis of PBZ and comparison to the other sampling areas (IZ, 
NZ and TZ) (Ktrans: permeability constant, Ve: fractional volume of extravascular extracellular space, s0: initial 
slope, s30, s60 and s360: slope at 30 sec, 60 sec and 360 sec respectively, ∆R1max: maximum longitudinal 
relaxation rate variation, TTP: time to peak, AUC: area under the curve, T10: longitudinal relaxation time before 
gadolinium injection). 
 
Primary cultures 
 PBZ from 19 patients were used for cell cultures. Biopsy specimens were minced and mechanically 
dissociated in Dulbecco’s modified Eagles’ medium-high glucose (DMEM-HG) (Lonza, Verviers, Belgium). 
The resulting suspension was seeded in T80 flasks (Nunc, Dominique Dutscher, Brumath, France) containing 
DMEM-HG supplemented with 10% human AB serum (EFS, Lyon, France) and 1% antibiotics (Sigma-Aldrich, 
Saint Quentin Fallavier, France). Cells were grown at 37°C in a humidified incubator, under an atmosphere 
containing 5% CO2, and the medium was changed twice weekly. Contrast-phase microscopy was used to 
examine cells at passage 1 or 2. 
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Results 
Radiological analysis 
 We examined NZ, TZ, IZ and PBZ of seven patients with GB by DCE-MRI. 
 The comparison of the four zones in a multivariate analysis shows significant differences in all 
variables, except for s360 and T10 (Figure 1B). The PBZ presents lower values of ktrans and ve than the TZ, 
indicating that the blood-brain barrier was preserved in the PBZ, in contrast to the TZ. Contrast enhancement 
was also lower in the PBZ than in the TZ and the AUC of contrast enhancement over time was significantly 
lower in the PBZ. We found that PBZ enhancement curves were consistent, except for patient GB-09. All 
constants were high for this patient, although they were not statistically different from those of other samples. 
 These results suggest that the DCE-MRI properties of the PBZ were similar to those of normal brain 
previously described by Tofts [25]. This was expected because PBZ was defined in our study as a radiologically 
normal peritumoral tissue, located at a distance from the brain/tumor interface, with the absence of gadolinium 
enhancement and a normal aspect on T1-weighted sequences. 
Histopathological analysis 
 All PBZ samples were considered macroscopically similar to normal brain under surgical microscope 
magnification. Histological analysis showed no abnormalities for 20 of the 28 biopsies (71%). We observed mild 
tumor cell infiltration in six patients (21%) and marked infiltration in two patients (7%) (Supplementary Table 
1). 
Flow cytometry analysis 
 Analysis of DNA index by flow cytometry is highly informative only if the tumor is aneuploid. We 
analyzed PBZ and TZ samples from 25 patients; eight (32%) did not contain an aneuploid cell population, thus 
flow cytometry could not be applied to assess tumor cell infiltration in these PBZ. Among the 17 patients with an 
aneuploid cell population in their TZ, eight (47%) displayed aneuploid cells in the PBZ and the percentage of 
aneuploid cells in the PBZ ranged from 3 to 44% (Table 1).  
 Interestingly, for a few samples (GB04, GB-09, GB-10 and GB-12), the PBZ contained only a few of 
the aneuploid cell populations identified in the TZ. This suggests that some tumor clones, but not all, migrate 
away from the tumor core. 
 Histopathology and flow cytometry gave similar results because all PBZ with a normal flow cytometry 
profile were considered free of tumor cell infiltration by histopathological analysis. However, flow cytometry 
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was more a sensitive approach to detect tumor cell infiltration than histopathological analysis, because three PBZ 
with an aneuploid cell population were identified as histologically normal (GB-06, GB-09, and GB-12). 
 
Table 1: DNA index of TZ and their corresponding PBZ. All TZ presented in this table contained aneuploid cell 
populations (DI  <1 or >1). The percentage of aneuploid cells is indicated in brackets. 
 
 TZ PBZ 
GB-02 1 + 1.97 (13.5%) 1(0%) 
GB-03 1 + 0.95 (56%) 1 (0%) 
GB-04 1 + 0.9 + 1.8 (18%) 1 + 0.9 (24%) 
GB-05 1 + 0.9 + 1.8 (48%) 1 + 0.9 + 1.8 (30%) 
GB-06 1 + 1.8 (29%) 1 + 1.8 (3%) 
GB-07 1 + 2 + 2.3 (78%) 1 (0%) 
GB-08 1 + 1.43 (76%) 1 (0%) 
GB-09 1 + 1.54 + 1.7 (57%) 1 + 1.7 (3%) 
GB-10 1 + 0.9 + 1.8 (57%) 1 + 0.9 (44%) 
GB-11 1 + 1.7 + 1.8 (21%) 1 (0%) 
GB-12 1 + 0.9 + 1.8 (39%) 1 + 0.9 (20%) 
GB-15 1 + 1.05 + 2.05 (55%) 1 + 1.05 + 2.05 (26%) 
GB-21 1 + 1.45 (18%) 1 (0%) 
GB-29 1 + 1.04 + 2.01 (84%) 1 (0%) 
GB-32 1 + 1.06 + 2.08 (76%) 1 (0%) 
GB-34 1 + 0.96 (22%) 1 + 0.96 (33%) 
GB-37 1 + 0.95 (50%) 1 (0%) 
 
Genomic analysis 
 Array-CGH analysis of TZ showed genomic alterations commonly described in GB, such as gain of 
chromosome 7 with EGFR amplification, deletion of chromosome 10, and loss of CDKN2A/2B on chromosome 
9 (Aubry et al., submitted). 
 Six of the ten PBZ analyzed (GB-03, GB-09, GB-16, GB-17, GB-25, and GB-26) showed less than 1% 
of genome aberrations. The other four PBZ samples (GB-10, GB-15, GB-35, and GB-36) exhibited various large 
genomic alterations that were also present in tumor samples from these patients (Figure 2A). Individual array-
CGH profiles for each PBZ sample are available as supplementary data. The results of genomic analysis were 
correlated with those from histopathological analysis. All of the PBZ that were characterized as abnormal by 
genomic analysis exhibited tumor cell infiltration on microscopic examination. All the PBZ with minimal 
genomic alteration (< 1%) did not show tumor cell infiltration on histopathological analysis, except for the PBZ 
of GB-17, which exhibited a mild tumor cell infiltration. 
 Similar to findings from the flow cytometry analysis, abnormal PBZ samples exhibited only a few of 
the genetic alterations present in their respective TZ sample. For example, the CDKN2A/2B deletion was present 
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in almost all TZ whereas only one PBZ harbored this anomaly (GB-36). The deletion of chromosome 10 and the 
gain of chromosome 7 with the EGFR (7p11) amplification were found in both altered PBZ and their respective 
TZ.  
Transcriptomic analysis 
 The hierarchical clustering of transcriptomic data from nine PBZ and TZ samples, and four control 
brain samples distinguished two main clusters: one cluster grouping the PBZ with the control brain samples and 
the TZ from GB-09, and a second cluster comprising the remaining TZ (Figure 2B). 
 The PBZ and the control brain cluster could be further divided into two subgroups. The first subgroup 
comprised the control brain samples and the PBZ from GB-09, GB-16, GB-25, and GB-26. These PBZ did not 
show tumor cell infiltration on histopathological analysis and displayed minimal genomic alterations. Only the 
PBZ from GB-09 presented a tumor-related flow cytometry profile characterized by a rare aneuploid cell 
population (3%). The second subgroup, which clustered closer to the TZ sample cluster than the first subgroup, 
comprised the TZ from GB-09 and the PBZ from GB-03, GB-15, GB-17, GB-35, and GB-36. These PBZ 
displayed tumor cell infiltration on histopathology and/or an altered genomic profile, with the exception of GB-
03 PBZ. 
These results indicate that tumor infiltration in the PBZ alters the transcriptomic profile of this region but is 
not sufficient for PBZ and control brain samples to form separate clusters in transcriptomic analysis. The inter-
patient heterogeneity of PBZ samples as well as the low number of samples analyzed did not allow us to identify 
genes that were differentially expressed between PBZ and control brain samples. Such genes could be markers 
of recurrence mechanisms.  
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Fig. 2: 
A) Most frequent genomic alterations found in the PBZ and the TZ. 
B) Dendrogram of hierarchical clustering of brain samples based on the 1000 most differentially expressed genes 
between PBZ and TZ. Two main clusters of samples are observed: one cluster grouping the PBZ with the control 
brain samples (NB) and the TZ from GB-09, and a second cluster comprising the remaining TZ. 
 
Proteomic analysis 
We used the ICPL (isotope coded protein labeling) technique to examine the protein content of PBZ 
samples compared to their respective TZ samples and found that between 47 and 83% of proteins were 
differentially expressed between PBZ and TZ samples (Table 2). Similarly, a large proportion (44 to 83%) of 
proteins were differentially expressed between PBZ samples and pooled samples from control brain (Table 2). 
More detailed proteomic analyses are available in our previous studies [17, 18]. 
We assumed from these two comparative analyses that the PBZ can be considered as infiltrated if the 
number of differentially expressed proteins between the PBZ and the TZ is smaller than that between the PBZ 
and control brain. However, PBZ that were classified as infiltrated according to these parameters did not match 
those identified as infiltrated by histopathological examination. Thus, the PBZ harbored a proteomic profile 
distinct from that of TZ and control brain regardless of histological profile. As for the transcriptomic analysis, 
the identification of a proteomic profile specific to the PBZ was not possible and requires a larger cohort of 
samples. 
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Table 2: Differential proteomic profile between PBZ and NB, and between PBZ and TZ 
 
 
PBZ vs NB  PBZ vs TZ 
 
IdProt Quant Prot Diff Prot 
 IdProt Quant Prot Diff Prot 
GB-03 145 58 48 (83%)  267 105 49 (47%) 
GB-10 123 72 32 (44%)  273 135 82 (61%) 
GB-16 145 72 53 (74%)  258 114 72 (63%) 
GB-22 116 55 44 (80%)  266 96 62 (65%) 
GB-25 123 58 44 (76%)  321 90 75 (83%) 
GB-26 116 55 36 (65%)  - - - 
 
NB: normal brain, IdProt: number of unique identified proteins, QuantProt: number of unique quantified 
proteins, DiffProt: number of unique quantified proteins that are differentially expressed between PBZ and the 
control sample. A threshold of < 0.71 was used for under-expressed proteins and > 1.41 was used for over-
expressed proteins. Percentage of differentially expressed proteins (from the total number of unique quantified 
proteins) is displayed in brackets. 
 
Primary cultures 
 We examined primary cultures of 19 samples of PBZ and TZ by phase-contrast microscopy. Six (32%) 
of the PBZ cultures gave rise to tumor-like cells with a morphology similar to that of GB cells derived from their 
respective TZ sample (Figure 3, supplementary Table 2). These cells were spindle-shaped or clumped into 
irregular spheroids, often several layers thick. These PBZ samples, except for GB-11 PBZ, displayed tumor cell 
infiltration on histopathological and/or flow cytometry analyses. The other PBZ samples (68%) devoid of tumor 
cells on histopathological and/or flow cytometry analyses gave rise to diploid cells that we called GB-associated 
stromal cells (GASCs). These cells were star-shaped, were unable to assemble into multiple-layered structures as 
shown for GB-03 (Figure 3), and could be maintained in culture until passage 10. We recently showed that these 
stromal cells, despite their normal genomic profile, may display tumorigenic properties similar to myofibroblasts 
or cancer-associated fibroblasts (CAFs) in carcinoma [15, 16]. 
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Fig. 3: 
A) Flow cytometry histograms showing the DNA content of TZ biopsies (GB-03, GB-09 and GB-10) and their 
respective PBZ. A DI value of 1 was classified as DNA diploid and DI values of < 1 or > 1 were classified as 
aneuploid. 
B) Phase-contrast microscopy of primary cultures of TZ biopsies (GB-03, GB-09 and GB-10) and their 
respective PBZ (P1 or P2). Cells derived from TZ cultures were spindle-shaped and clumped into irregular 
spheroids, often several layers thick. PBZ cultures from GB-09 and GB10, in which tumor cells were present to 
a significant level in the biopsy specimen before culture, these cells proliferated. In the PBZ culture from GB-03 
in which tumor cells were absent, cell culture led, after two passages, to a diploid cell population. These diploid 
cells, which we called GASCs, were star-shaped and unable to assembly into multiple-layered structures. The 
bar indicates 50 µm. 
 
Discussion 
 Although the PBZ is largely considered as abnormal, this study is the first to analyze the PBZ via a 
multidisciplinary approach, and paints a picture of a PBZ that is normal from afar but far from normal. 
Normal from afar … 
 Radiological and macroscopic analyses revealed that the PBZ resembled normal brain tissue. The PBZ 
presented a homogeneous DCE profile similar to that of normal brain but unlike that of the other sampling zones 
of GB. This radiological profile was characterized by low permeability and low extracellular volume fraction. 
This reflects the maintenance of the blood-brain barrier in the PBZ, which would explain the absence of contrast 
enhancement because the permeability in DCE imaging is proportional to the tumor histopathological grade [26]. 
However, radiological analysis of low-grade glioma has shown that tumor infiltration may be present without 
neoangiogenesis, thus without contrast enhancement and that the tumoral cell density threshold to modify the 
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MRI signal must be around 500 cells/mm3 [27], showing the limitations of radiological examination to 
apprehend glial tumor’s infiltration in the brain parenchyma. This is highlighted by the results of 
histopathological examination that found tumor cell infiltration in one third of radiologically normal PBZ. 
Other pre-surgical MRI techniques such as diffusion- and perfusion-weighted imaging and spectroscopy 
may be useful to evaluate tumor cell infiltration in PBZ. These approaches have already been used to assess the 
histological nature of the adjacent tumor [28–30] or the WHO grade of glial tumors [31, 32]. The authors of a 
recent study used diffusion tensor imaging sequences to assess PBZ infiltration and showed that vasogenic 
edema and tumor-infiltrated edema are characterized by distinct patterns in imaging data [33]. Further 
radiological studies that take into account this interesting result may be able to refine the pre-operative 
evaluation of PBZ infiltration, which may challenge traditional surgical strategies based on the removal of the 
contrast-enhanced tumor. In parallel, per-operative analysis of the resection margin, and thus of the PBZ, is 
currently increasingly performed during surgery, with the development of intra-operative CT or MRI and 
fluorescence–guided surgery with 5-aminolevulinic acid [5, 34, 35]. 
… But far from normal 
 As indicated above, histopathological examination found tumor cell infiltration in one third of PBZ in 
contrast with radiological and macroscopic analyses, which is consistent with data from the literature [9–11, 36]. 
Flow cytometry, genomic, transcriptomic, and primary cell culture approaches also identified these neoplastic 
features in these PBZ. Flow cytometry and primary culture analyses were more sensitive than histological 
analyses because they were able to identify tumor cell infiltration in histologically normal PBZ.  
 Proteomic and transcriptomic analyses showed that the RNA and protein content of the PBZ is 
distinct from that of both the TZ and control brain. However, due to the inter-patient heterogeneity of the PBZ, 
we were unable to identify specific markers that could be involved in recurrence mechanisms. A large cohort of 
PBZ samples is necessary to identify such markers, but the constitution of such a cohort faces the ethical issue of 
sampling “normal” brain tissue around the tumor. Furthermore, the identification of markers is also made 
difficult by the choice of the brain control sample to be used. Obviously, brain samples from healthy, living 
individuals are difficult to obtain and the control samples commonly used include tissue obtained during brain 
surgery for pathological conditions such as epilepsy, with the informed consent of the patient. However, we 
showed recently that epilepsy samples have a “tumoral” protein expression pattern [17]; thus, caution should be 
urged about the use of these samples as control samples. Post-mortem brain tissue obtained from autopsy is a 
potential, alternative source of brain control samples. However, RNA and several highly abundant proteins are 
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degraded rapidly after death [37, 38]; therefore, the use of such control brain samples necessitates quick 
sampling and storage, which are difficult to implement. These observations show that it is a major obstacle to 
find brain control samples with a proteome and transcriptome that are similar to that normally present in vivo. 
Although we have not identified representative markers of the PBZ through transcriptomic and proteomic 
analyses, we observed specific alterations of this area through genomic, flow cytometry and primary culture 
analyses. We show that the PBZ possesses some, but not all, of the tumor cell alterations found in the TZ. In 
particular, genomic analyses indicated that the deletion of chromosome 10 and the EGFR (7p11) amplification 
present in the TZ were also present in PBZ, whereas the CDKN2A/B deletion, which was also present in the TZ, 
was in most cases absent from the PBZ. The amplification of EGFR in the PBZ was also described by Mangiola 
et al. (2013) [39]. These results suggest that copy number alterations targeting chromosome 7 and 10 are among 
the earliest events in GB tumor evolution and that some tumor clones, but not all, migrate away from the tumor. 
Some studies have reported findings that support this suggestion [12–14]. For example, Glas et al. (2010) used 
primary cultures to isolate tumor cells from the brain tissue surrounding the resection cavity [12]. These 
infiltrating tumor cells displayed genetic alterations typical of GB, but could be distinguished from tumor cells 
isolated from the tumor core on the basis of their distinctive molecular profiles and responses to drugs and 
irradiation in vitro. Similarly, Piccirillo et al. (2012) used fluorescence-guided surgical sampling of GB to 
identify phenotypically distinct tumor-initiating cell populations in the tumor mass and margins [13]. Our 
observations in primary cultures show that the PBZ can be altered even in the absence of tumor cell infiltration. 
We isolated a population of stromal cells that we named GASCs, which share phenotypic and functional 
properties with CAFs described in the stroma of carcinomas. In particular, they have a myofibroblast phenotype 
and tumorigenic and angiogenic properties [15, 16]. GASCs may be implicated in recurrence mechanisms of GB 
as infiltrating tumor cells. 
 
Conclusion 
This multidisciplinary analysis of the PBZ confirms that macroscopic and radiological analyses are 
insufficient to determine whether the PBZ has an abnormal profile. Omic analyses highlight the complexity of 
this zone, which shows inter-patient variability similar to its corresponding tumor zone. This complexity makes 
it difficult to identify representative markers of the PBZ. The observation of select tumor clones in the PBZ and 
the presence of stromal cells with tumorigenic and angiogenic properties emphasizes the importance to 
characterize better this area in order to: 1) develop approaches to refine the per-operative evaluation of the PBZ 
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to optimize the surgical resection of the tumor, and 2) improve the understanding of mechanisms that underlie 
GB recurrence to develop new therapies. 
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Supplementary methods 
Radiological analysis 
Standardized sequences were used for pre-surgical MRI at each participating center and were carried out in 
the following order: T1-weighted axial and coronal acquisitions, diffusion, a quantitative dynamic contrast-
enhanced (DCE) session after the injection of gadoteric acid at a concentration of 0.1 mmol/kg, and finally T2 
FLAIR, T2-weighted and 3D T1 acquisitions. 
Preliminary quality controls were performed at each center to ensure that acquisitions between the different 
sites were similar. Signal homogeneity, geometric distortions, spatial resolution, slice position, and MRI 
acquisition parameters were controlled between the different MR scanners 29. Images were written onto a CD-
ROM and transferred to the reference center for centralized interpretation (Functional imaging platform PRISM, 
Cancéropôle Grand Ouest, Rennes, France). 
Quantitative and semi-quantitative DCE-MRI variables were calculated in all four zones (NZ, TZ, IZ and 
PBZ) for seven patients, with a DCE-MRI protocol adapted from a previous study 11. 2D Spoiled Gradient Echo 
sequences (TR/TE = 150/5.6 ms and variable flip angle, θ1 = 10°, θ2 = 90°) were performed. Thirteen sagittal 
slices were acquired with a field of view of 180 mm x 240 mm, a slice thickness of 5 mm, and a 192 x 256 
matrix leading to spatial resolution of 0.94 mm x 0.94 mm. Five longitudinal relaxation time (T1) calibration 
vials were positioned in the coil and were simultaneously imaged with the patient. 
Images were corrected for head movements prior to DCE-MRI post-processing with 3D Slicer 
(www.slicer.org) and variables were calculated with Matlab (MATLAB and Statistics Toolbox Release 2012b, 
The MathWorks, Inc., Natick, MA, USA). We were able to extract several variables from the DCE-MRI curves; 
the transfer constant (ktrans), which reflects capillary permeability, the fractional volume (ve) of extravascular 
extracellular space, which indicates the tissue fraction accessible to the contrast agent, and other variables [s0, 
s30, s60, s360, the maximal relaxation rate variation (∆R1max), time to peak (TTP), the area under the curve 
(AUC), and the longitudinal relaxation time (T10)]. The experimental data were adjusted with the Tofts 
experimental model to extract characteristics of the different sampling zones 39. 
Statistical analysis was carried out with ANOVA for multivariate analysis and post-hoc analysis was carried 
out with an LSD test and a T3 Dunnett’s test. Alpha risk was set at 5 %. 
 
Genomic and transcriptomic analyses 
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PBZ and TZ samples from ten patients were used for genomic analyses and samples from nine patients were 
used for transcriptomic analyses. We also used four samples of control brain parenchyma that were obtained 
from patients who underwent cortectomy for epilepsy, as a control for transcriptomic analysis. Total DNA was 
isolated with Nucleospin tissue kit and total RNA was isolated with the NucleoSpin RNAII kit (both from 
Macherey–Nagel, Hoerdt, France). DNA quality was assessed by electrophoresis in a 1% agarose gel. RNA 
integrity (RNA integrity NC8) was confirmed with an Agilent 2100 bioanalyzer (Agilent Technologies, Santa 
Clara, CA, USA). 
The full procedure for the analysis of genomic data is described in one of our previous publications 9. 
Briefly, genomic alteration profiles were obtained by comparing copy number variation between DNA extracted 
from the sampling zones and matching constitutional DNA by HaarSeg and CGHcall methods with waviCGH 
software 2. Comparisons between PBZ and TZ copy number alteration profiles were extracted from the TuMult 
analysis performed with all the samples included in the original study 19. Analysis of gene expression profiles 
was restricted to TZ and PBZ and was performed with TMeV software 30. Probes were selected on the basis of 
their expression levels (intensity greater than 100 in at least one of the two conditions). The 1000 most 
differentially expressed genes between PBZ and TZ were identified by a two-class paired SAM (Significant 
Analysis of Microarray). PBZ, TZ, and CB samples were grouped by hierarchical clustering with average 
linkage and Euclidean distance. 
 
Proteomic analysis 
The isotope-coded protein labeling technique (ICPL) was used to analyze PBZ and TZ samples from six 
patients and the proteomic profile of PBZ was compared to that of TZ. Pooled brain samples from three patients 
who underwent epilepsy surgery were used as control brain samples. During the ICPL method, intact proteins 
are labeled with isotopic derivatives of nicotinic acid of different molecular weights; this is followed first by gel 
liquid chromatography and subsequently by tandem mass spectrometry (GeLC-MS/MS) to identify and quantify 
proteins with an Esquire HCT Ultra PTM Discovery mass spectrometer. Detailed methodological information 
about ICPL is available in our previous publications 7,18. 
Peptides were identified by querying the human Swiss-Prot database with the Mascot search engine 
(v2.2.07), applying a score above the identity threshold and a false discovery rate (FDR) < 1%. The 
ProteinExtractor algorithm in the ProteinScape 2.0 software was used to compile the identified peptides into a 
non-redundant protein list. Relative quantification of labeled peptides was determined for each sample with the 
 19
WarpLC 1.2 software. The threshold of differential expression between PBZ and CB samples, and between PBZ 
and TZ samples, was set to > 1.41 for up-regulated proteins and < 0.71 for down-regulated proteins, which is 
above the calculated technical variation of the method 7. 
 
Références 
1.  Eliat P-A, Olivié D, Saïkali S, Carsin B, Saint-Jalmes H, de Certaines JD. Can dynamic contrast-enhanced 
magnetic resonance imaging combined with texture analysis differentiate malignant glioneuronal tumors 
from other glioblastoma? Neurol Res Int. 2012;2012:195176.  
2.  Tofts PS, Kermode AG. Measurement of the blood-brain barrier permeability and leakage space using 
dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med Off J Soc Magn Reson Med Soc Magn 
Reson Med. 1991 Feb;17(2):357–67.  
3.  De Tayrac M, Etcheverry A, Aubry M, Saïkali S, Hamlat A, Quillien V, et al. Integrative genome-wide 
analysis reveals a robust genomic glioblastoma signature associated with copy number driving changes in 
gene expression. Genes Chromosomes Cancer. 2009 Jan;48(1):55–68.  
4.  Carro A, Rico D, Rueda OM, Díaz-Uriarte R, Pisano DG. waviCGH: a web application for the analysis and 
visualization of genomic copy number alterations. Nucleic Acids Res. 2010 Jul;38(Web Server 
issue):W182–187.  
5.  Letouzé E, Allory Y, Bollet MA, Radvanyi F, Guyon F. Analysis of the copy number profiles of several 
tumor samples from the same patient reveals the successive steps in tumorigenesis. Genome Biol. 
2010;11(7):R76.  
6.  Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N, et al. TM4: a free, open-source system for 
microarray data management and analysis. BioTechniques. 2003 Feb;34(2):374–8.  
7.  Com E, Clavreul A, Lagarrigue M, Michalak S, Menei P, Pineau C. Quantitative proteomic Isotope-Coded 
Protein Label (ICPL) analysis reveals alteration of several functional processes in the glioblastoma. J 
Proteomics. 2012 Jul 16;75(13):3898–913.  
8.  Lemée J-M, Com E, Clavreul A, Avril T, Quillien V, de Tayrac M, et al. Proteomic analysis of 
glioblastomas: what is the best brain control sample? J Proteomics. 2013 Jun 24;85:165–73.  
  
